Multiple effects of TRAIL in human carcinoma cells: Induction of apoptosis, senescence, proliferation, and cytokine production

Experimental Cell Research

Volumn 314, Issue 7, 2008, Pages 1605-1616

  Levina, Vera ^a   Marrangoni, Adele M ^a   DeMarco, Richard ^a   Gorelik, Elieser ^a,b   Lokshin, Anna E ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Apoptosis; Caspases; Cell proliferation; Cytokines; Senescence; TRAIL

Indexed keywords

CASPASE 8; CASPASE 9; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 2A; FIBROBLAST GROWTH FACTOR; HIGH MOBILITY GROUP A PROTEIN; INTERLEUKIN 1BETA CONVERTING ENZYME; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1; RANTES; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

APOPTOSIS; ARTICLE; CARCINOMA CELL; CELL AGING; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; ENZYME INHIBITION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 40949129917     PISSN: 00144827     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yexcr.2007.12.027     Document Type: Article

References (51)

1. Ashkenazi A., Pai R.C., Fong S., Leung S., Lawrence D.A., Marsters S.A., Blackie C., Chang L., McMurtrey A.E., Hebert A., DeForge L., Koumenis I.L., Lewis D., Harris L., Bussiere J., Koeppen H., Shahrokh Z., and Schwall R.H. Safety and antitumor activity of recombinant soluble Apo2 ligand. J. Clin. Invest. 104 (1999) 155-162
2. Kischkel F.C., Lawrence D.A., Chuntharapai A., Schow P., Kim K.J., and Ashkenazi A. Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5. Immunity 12 (2000) 611-620
3. Zhang L., and Fang B. Mechanisms of resistance to TRAIL-induced apoptosis in cancer. Cancer Gene Ther. 12 (2005) 228-237
4. Eggert A., Grotzer M.A., Zuzak T.J., Wiewrodt B.R., Ikegaki N., and Brodeur G.M. Resistance to TRAIL-induced apoptosis in neuroblastoma cells correlates with a loss of caspase-8 expression. Med. Pediatr. Oncol. 35 (2000) 603-607
5. Kim K., Fisher M.J., Xu S.Q., and el-Deiry W.S. Molecular determinants of response to TRAIL in killing of normal and cancer cells. Clin. Cancer Res. 6 (2000) 335-346
6. Kreuz S., Siegmund D., Scheurich P., and Wajant H. NF-kappaB inducers upregulate cFLIP, a cycloheximide-sensitive inhibitor of death receptor signaling. Mol. Cell. Biol. 21 (2001) 3964-3973
7. Nesterov A., Lu X., Johnson M., Miller G.J., Ivashchenko Y., and Kraft A.S. Elevated AKT activity protects the prostate cancer cell line LNCaP from TRAIL-induced apoptosis. J. Biol. Chem. 276 (2001) 10767-10774
8. Baader E., Toloczko A., Fuchs U., Schmid I., Beltinger C., Ehrhardt H., Debatin K.M., and Jeremias I. Tumor necrosis factor-related apoptosis-inducing ligand-mediated proliferation of tumor cells with receptor-proximal apoptosis defects. Cancer Res. 65 (2005) 7888-7895
9. Secchiero P., Zerbinati C., Rimondi E., Corallini F., Milani D., Grill V., Forti G., Capitani S., and Zauli G. TRAIL promotes the survival, migration and proliferation of vascular smooth muscle cells. Cell. Mol. Life Sci. 61 (2004) 1965-1974
10. Morel J., Audo R., Hahne M., and Combe B. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) induces rheumatoid arthritis synovial fibroblast proliferation through mitogen-activated protein kinases and phosphatidylinositol 3-kinase/Akt. J. Biol. Chem. 280 (2005) 15709-15718
11. Ehrlich S., Infante-Duarte C., Seeger B., and Zipp F. Regulation of soluble and surface-bound TRAIL in human T cells, B cells, and monocytes. Cytokine 24 (2003) 244-253
12. Ehrhardt H., Fulda S., Schmid I., Hiscott J., Debatin K.M., and Jeremias I. TRAIL induced survival and proliferation in cancer cells resistant towards TRAIL-induced apoptosis mediated by NF-kappaB. Oncogene 22 (2003) 3842-3852
13. Milani D., Zauli G., Rimondi E., Celeghini C., Marmiroli S., Narducci P., Capitani S., and Secchiero P. Tumour necrosis factor-related apoptosis-inducing ligand sequentially activates pro-survival and pro-apoptotic pathways in SK-N-MC neuronal cells. J. Neurochem. 86 (2003) 126-135
14. Trauzold A., Siegmund D., Schniewind B., Sipos B., Egberts J., Zorenkov D., Emme D., Roder C., Kalthoff H., and Wajant H. TRAIL promotes metastasis of human pancreatic ductal adenocarcinoma. Oncogene 25 (2006) 7434-7439
15. Li J.H., Kirkiles-Smith N.C., McNiff J.M., and Pober J.S. TRAIL induces apoptosis and inflammatory gene expression in human endothelial cells. J. Immunol. 171 (2003) 1526-1533
16. Abdollahi T., Robertson N.M., Abdollahi A., and Litwack G. Identification of interleukin 8 as an inhibitor of tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in the ovarian carcinoma cell line OVCAR3. Cancer Res. 63 (2003) 4521-4526
17. Siegmund D., Klose S., Zhou D., Baumann B., Roder C., Kalthoff H., Wajant H., and Trauzold A. Role of caspases in CD95L- and TRAIL-induced non-apoptotic signalling in pancreatic tumour cells. Cell. Signal. 19 (2007) 1172-1184
18. Varfolomeev E., Maecker H., Sharp D., Lawrence D., Renz M., Vucic D., and Ashkenazi A. Molecular determinants of kinase pathway activation by Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand. J. Biol. Chem. 280 (2005) 40599-40608
19. Ishimura N., Isomoto H., Bronk S.F., and Gores G.J. Trail induces cell migration and invasion in apoptosis-resistant cholangiocarcinoma cells. Am. J. Physiol.: Gasterointest. Liver Physiol. 290 (2006) G129-G136
20. Secchiero P., Gonelli A., Carnevale E., Corallini F., Rizzardi C., Zacchigna S., Melato M., and Zauli G. Evidence for a proangiogenic activity of TNF-related apoptosis-inducing ligand. Neoplasia 6 (2004) 364-373
21. Choi C., Kutsch O., Park J., Zhou T., Seol D.W., and Benveniste E.N. Tumor necrosis factor-related apoptosis-inducing ligand induces caspase-dependent interleukin-8 expression and apoptosis in human astroglioma cells. Mol. Cell. Biol. 22 (2002) 724-736
22. Almasan A., and Ashkenazi A. Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy. Cytokine Growth Factor Rev. 14 (2003) 337-348
23. Falschlehner C., Emmerich C.H., Gerlach B., and Walczak H. TRAIL signalling: decisions between life and death. Int. J. Biochem. Cell Biol. 39 (2007) 1462-1475
24. Lin A., and Karin M. NF-kappaB in cancer: a marked target. Semin. Cancer Biol. 13 (2003) 107-114
25. Joyce D., Albanese C., Steer J., Fu M., Bouzahzah B., and Pestell R.G. NF-kappaB and cell-cycle regulation: the cyclin connection. Cytokine Growth Factor Rev. 12 (2001) 73-90
26. Meloche S., and Pouyssegur J. The ERK1/2 mitogen-activated protein kinase pathway as a master regulator of the G1- to S-phase transition. Oncogene 26 (2007) 3227-3239
27. Li Q., and Zhu G.D. Targeting serine/threonine protein kinase B/Akt and cell-cycle checkpoint kinases for treating cancer. Curr. Top. Med. Chem. 2 (2002) 939-971
28. Roninson I.B. Tumor cell senescence in cancer treatment. Cancer Res. 63 (2003) 2705-2715
29. Campisi J. Aging, tumor suppression and cancer: high wire-act!. Mech. Ageing Dev. 126 (2005) 51-58
30. Zheng Q.H., Ma L.W., Zhu W.G., Zhang Z.Y., and Tong T.J. p21Waf1/Cip1 plays a critical role in modulating senescence through changes of DNA methylation. J. Cell. Biochem. 98 (2006) 1230-1248
31. Narita M., Krizhanovsky V., Nunez S., Chicas A., Hearn S.A., Myers M.P., and Lowe S.W. A novel role for high-mobility group A proteins in cellular senescence and heterochromatin formation. Cell 126 (2006) 503-514
32. Schmitt C.A. Cellular senescence and cancer treatment. Biochim. Biophys. Acta 1775 (2007) 5-20
33. Siervo-Sassi R.R., Marrangoni A.M., Feng X., Naoumova N., Winans M., Edwards R.P., and Lokshin A. Physiological and molecular effects of Apo2L/TRAIL and cisplatin in ovarian carcinoma cell lines. Cancer Lett. 190 (2003) 61-72
34. Gastman B., Wang K., Han J., Zhu Z.Y., Huang X., Wang G.Q., Rabinowich H., and Gorelik E. A novel apoptotic pathway as defined by lectin cellular initiation. Biochem. Biophys. Res. Commun. 316 (2004) 263-271
35. Gorelik E., Landsittel D.P., Marrangoni A.M., Modugno F., Velikokhatnaya L., Winans M.T., Bigbee W.L., Herberman R.B., and Lokshin A.E. Multiplexed immunobead-based cytokine profiling for early detection of ovarian cancer. Cancer Epidemiol. Biomarkers Prev. 14 (2005) 981-987
36. Marini P., Schmid A., Jendrossek V., Faltin H., Daniel P.T., Budach W., and Belka C. Irradiation specifically sensitises solid tumour cell lines to TRAIL mediated apoptosis. BMC Cancer 5 (2005) 5
37. Singh T.R., Shankar S., Chen X., Asim M., and Srivastava R.K. Synergistic interactions of chemotherapeutic drugs and tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand on apoptosis and on regression of breast carcinoma in vivo. Cancer Res. 63 (2003) 5390-5400
38. Richmond A. Nf-kappa B, chemokine gene transcription and tumour growth. Nat. Rev., Immunol. 2 (2002) 664-674
39. Andreakos E., Williams R.O., Wales J., Foxwell B.M., and Feldmann M. Activation of NF-kappaB by the intracellular expression of NF-kappaB-inducing kinase acts as a powerful vaccine adjuvant. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 14459-14464
40. Schmitt C.A., Fridman J.S., Yang M., Lee S., Baranov E., Hoffman R.M., and Lowe S.W. A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy. Cell 109 (2002) 335-346
41. Campisi J. Senescent cells, tumor suppression, and organismal aging: good citizens, bad neighbors. Cell 120 (2005) 513-522
42. Ravi R., Bedi G.C., Engstrom L.W., Zeng Q., Mookerjee B., Gelinas C., Fuchs E.J., and Bedi A. Regulation of death receptor expression and TRAIL/Apo2L-induced apoptosis by NF-kappaB. Nat. Cell Biol. 3 (2001) 409-416
43. Whang Y.E., Yuan X.J., Liu Y., Majumder S., and Lewis T.D. Regulation of sensitivity to TRAIL by the PTEN tumor suppressor. Vitam. Horm. 67 (2004) 409-426
44. Ben-Baruch A. The multifaceted roles of chemokines in malignancy. Cancer Metastasis Rev. 25 (2006) 357-371
45. Coussens L.M., and Werb Z. Inflammation and cancer. Nature 420 (2002) 860-867
46. Li A., Varney M.L., and Singh R.K. Expression of interleukin 8 and its receptors in human colon carcinoma cells with different metastatic potentials. Clin. Cancer Res. 7 (2001) 3298-3304
47. Azenshtein E., Luboshits G., Shina S., Neumark E., Shahbazian D., Weil M., Wigler N., Keydar I., and Ben-Baruch A. The CC chemokine RANTES in breast carcinoma progression: regulation of expression and potential mechanisms of promalignant activity. Cancer Res. 62 (2002) 1093-1102
48. Vaday G.G., Peehl D.M., Kadam P.A., and Lawrence D.M. Expression of CCL5 (RANTES) and CCR5 in prostate cancer. Prostate 66 (2006) 124-134
49. Bar-Eli M. Role of interleukin-8 in tumor growth and metastasis of human melanoma. Pathobiology 67 (1999) 12-18
50. Rebbaa A., Zheng X., Chou P.M., and Mirkin B.L. Caspase inhibition switches doxorubicin-induced apoptosis to senescence. Oncogene 22 (2003) 2805-2811
51. Minchinton A.I., and Tannock I.F. Drug penetration in solid tumours. Nat. Rev. Cancer 6 (2006) 583-592